3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled